Erste Group Bank Has Negative Outlook of ABT FY2027 Earnings

Abbott Laboratories (NYSE:ABT) – Equities researchers at Erste Group Bank reduced their FY2027 EPS estimates for shares of Abbott Laboratories in a research note issued on Friday, June 5th. Erste Group Bank analyst H. Engel now forecasts that the healthcare product maker will earn $6.04 per share for the year, down from their prior forecast of $6.05. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.48 per share.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS.

A number of other equities analysts have also issued reports on the stock. Oppenheimer decreased their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Evercore cut their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. cut their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Citigroup cut their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Abbott Laboratories Stock Performance

Shares of ABT opened at $89.15 on Thursday. The firm has a 50-day moving average price of $92.01 and a 200 day moving average price of $108.39. The firm has a market capitalization of $155.29 billion, a PE ratio of 24.97, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Abbott Laboratories

A number of hedge funds have recently bought and sold shares of the company. Freemont Management S.A. lifted its position in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $116,580,000. Thrivent Financial for Lutherans lifted its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the third quarter worth approximately $185,640,000. Finally, Net Worth Advisory Group purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $1,366,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.